Drug Rescue
Innovation Worth Watching: How Ignota Labs Leverages AI to Rescue Promising but Failing Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-25-NI-06Aug 6, 2025
Cloud-Based Platform
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
Charles River Laboratories
PR-M03-23-03Mar 14, 2023
Cosmeceuticals
Cosmeceuticals Are Here. When Will Regulations Catch Up?
Ameena Pathan
That's Nice LLC
PAO-08-022-CL-09Aug 31, 2022
Regulatory
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
U.S. Food & Drug Administration
PR-M03-22-03Mar 7, 2022
Option Agreement
Merck KGaA, Darmstadt, Germany, Enters Into Option Agreement With Quris on Its BioAI Platform for Clinical Safety Prediction
Quris
PR-M02-22-08Feb 9, 2022
Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation
Thomas Briel, Ph.D.; Moritz Beck-Broichsitter, Ph.D.
MilliporeSigma
PA141Jan 28, 2022
Safety Evaluation
ACCP Releases Policy Statements
American College of Clinical Pharmacology
PR-M01-22-07Jan 11, 2022
Process Development
Designing More Sustainable Small Molecule API Manufacturing Processes
Arne Grumann; Marko Salo
Fermion
PAO-09-21-CL-05Sep 16, 2021
Pharmacovigilance
The Evolution of Drug Safety
Arriello
PAO-04-22-R221-53Apr 21, 2021
Fecal Transplant
Fecal Transplant Associated with One Patient Death
Pharma's Almanac
PAO-M06-19-NI-020Jun 21, 2019
FDA Action
FDA Orders Manufacturers of Surgical Mesh Intended for Transvaginal Repair of Pelvic Organ Prolapse to Stop Selling All Devices
U.S. Food & Drug Administration
PR-M04-19-NI-060Apr 18, 2019
Safety Labeling
FDA Orders Important Safety Labeling Changes for Addyi
U.S. Food & Drug Administration
PR-M04-19-NI-045Apr 15, 2019
Public Health
FDA and CBP Bolster Collaboration to Protect Public Health and Safety
U.S. Food & Drug Administration
PR-M04-19-NI-034Apr 10, 2019
FDA
Statement from FDA on the Agency's List of Known Nitrosamine-free Valsartan and ARB Class Medicines
U.S. Food & Drug Administration
PR-M04-19-NI-035Apr 10, 2019
Stem Cells
Statement by FDA on Efforts to Stop Stem Cell Clinics and Manufacturers from Marketing Unapproved Products and Advance Legitimate Development
U.S. Food & Drug Administration
PR-M04-19-NI-031Apr 9, 2019
Drug Safety
BioIVT Launches Its XPRESSWAY® Profile Safety Package, a Gene Expression Reference Guide Designed to Improve Drug Safety Analyses
BioIVT
PR-M03-19-NI-024Mar 8, 2019
Quality Metrics
FDA Makes More Quality Moves
Nigel Walker
Nice Insight
PAO-M08-18-NI-006Jul 31, 2018
Process Safety Evaluations Crucial to Successful CDMO Operations
Vince Ammoscato, M.Sc.; Sean Lapekas
Ash Stevens
PAP-Q02-16-CL-009Apr 1, 2016